ArticleDiabetes, obesity & metabolism2026
Prescribing of glucose-lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular Outcomes Among Adults with Type 2 Diabetes or Obesity Receiving Carbohydrate-Reduced Nutrition via Telemedicine: A Retrospective Claims-Based Cohort Study.Cardiology and therapy · 2026Article
- Prescribing of glucose-lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimWe aimed to determine whether glucose-lowering medication (GLM) prescribing differs by severe mental illness (SMI) status. MATERIALS AND
methodsWe conducted a population-based cohort study using routinely collected linked data, including people in Scotland diagnosed with type 2 diabetes between January 2004 and March 2022. We used Cox proportional hazards models to compare the time from diabetes diagnosis to the first prescription of each of metformin and insulin in people with and without a hospital admission record of SMI (schizophrenia, bipolar disorder or depression prior to diabetes diagnosis). We adjusted for age, sex, area-based socio-economic deprivation, smoking status and baseline HbA1c and estimated glomerular filtration rate.
resultsAmong 317 761 people with type 2 diabetes, 14 600 (4.6%) had pre-existing SMI. During a median follow-up of 1.6 years, 10 859 (74%) of those with SMI and 219 823 (73%) without SMI were prescribed metformin. After accounting for confounders, people with SMI received their first metformin (HR 1.09, 95% CI: 1.07-1.11) and insulin (HR 1.24, 95% CI: 1.18-1.31) prescriptions at a faster rate than people without SMI. Body mass index (BMI) was missing in 21% of participants, but similar estimates were obtained when we additionally adjusted for BMI in analyses that only included people with BMI data.
conclusionsAmong people with type 2 diabetes each of metformin and insulin is prescribed sooner in people with compared to those without SMI. Further research is needed to understand the reasons for this, and to investigate the implications of these differences in prescribing patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.